Medicus Pharma Announces Successful Phase 2 Results for SkinJect Therapy

Key Facts

1All 90 enrolled patients in the Phase 2 study of SkinJect therapy completed treatment without discontinuations.

In a move reflecting progress within the biotech sector's rare disease pipeline, Medicus Pharma has announced successful completion of its Phase 2 trial for SkinJect. According to reports, all 90 enrolled patients finished the treatment protocol without any discontinuations. The randomized study, which compared two dose levels against a microneedle comparator, provides the clinical foundation for the company's next-stage registrational trials.

These findings support the company's strategic shift toward its FDA-authorized SKNJCT-005 program for patients with Gorlin syndrome. Per market data, MDCX shares closed at $0.1704 on September 9, 2026, having traded between a day low of $0.1636 and a high of $0.1718. The clinical data package is expected to facilitate ongoing discussions with potential partners interested in advancing the therapy for broader indications.

Traders should watch for price stability around the $0.1704 level (close September 9, 2026) as the company progresses with its regulatory applications. While the upcoming economic calendar shows no direct catalysts for the firm in the next week, the successful trial completion remains the primary driver for sentiment in the immediate term.